Cooley Advises Horizon Pharma on $660 Million Acquisition of Vidara Therapeutics

San Diego, Calif. – March 27, 2014 – Cooley LLP announced today that it advised Horizon Pharma, Inc. on its acquisition of Dublin-based Vidara Therapeutics International Ltd. for stock and cash valued at approximately $660 million. The resulting company, which will be organized under the laws of Ireland, has a portfolio of four products marketed primarily in the US. The transaction is expected to close by mid-2014.
 
Horizon is a commercial stage, specialty pharmaceutical company that markets DUEXIS®, VIMOVO® and RAYOS®/LODOTRA®, which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. Horizon's strategy is to develop, acquire or in-license additional innovative medicines where it can execute a targeted commercial approach to specific physicians, such as primary care physicians, orthopedic surgeons and rheumatologists, while leveraging its commercial strengths and the infrastructure the company has put in place. Vidara is a specialty pharmaceutical company that markets ACTIMMUNE® in the US and maintains operations both in Dublin, Ireland and in the US. 

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

Related Contacts
Kay Chandler Partner, San Diego
Mischi a Marca Partner, San Francisco
Michelle Lara Special Counsel, San Diego
Sean Clayton Partner, San Diego
Natasha Leskovsek Partner, Washington, DC
Wade Andrews Associate, San Diego
Jacqueline Grise Partner, Washington, DC
Matt Robbins Associate, San Diego
Ben Beerle Partner, San Francisco